the efficacy of a transdiagnostic emotion-focused exposure ... · the efficacy of a transdiagnostic...
TRANSCRIPT
The efficacy of a transdiagnostic emotion-focused exposure
treatment for chronic pain patients with comorbid anxiety and
depression.
A randomised controlled trial
2019-02-25 1
• Marked co-occurrence between chronic pain
and emotional problems
• Difficult to address parsimoniously and
effectively with available treatment options.
Why?
• Systemic problems
• Suboptimal results
2019-02-25 2
3
-2,5
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
2,5
LO32.1%
PF33.3%
SA19.5%
CO11.4%
SPSQ TSK
Wurm, Edlund, Tillfors & Boersma (2016). Scandinavian Journal of Pain
For pain patients with high levels of emotional problems,
CBT oriented pain treatments are generally less effective
- Chronic spinal pain
- CBT oriented multimodal rehabilitation
-1
-0,5
0
0,5
1
1,5Anxiety sensitivity
Negative affect
Anxiety
DepressionPain interference
Pain intensity
Low Return to workself-efficacy
PF-SA SC PF LO
Problem levels post TREATMENT
Wurm et al. 2016
For pain patients with high levels of emotional problems, CBT oriented
pain treatments are generally less effective
Emotional distress & cognitive behavioral factors
prognostic
5
Need for treatment innovation
• Important to test new treatment modalities for pain
patients with high levels of emotional problems
• Can we treat both emotional and pain problem simultaneously?
• Improve our theoretical understanding of the basis
for this comorbidity
• How do pain and emotion relate?
• A transdiagnostic perspective
• Emotional dysregulation
6
Transdiagnostic processes mutually reinforcing
and maintaining emotional dysregulation
Distress
Pain
problem
Emotional
problem
Functional impairment
EMOTION
REGULATION
Adapted from mutual maintenance model. From Sharp TJ, Harvey AG: Chronic pain and posttraumatic stress disorder: mutual maintenance?
Clinical Psychology Review 2001;21(6):857–77, p. 870
Hybrid exposure treatment for chronic
pain (Hybrid)
• Combines exposure in vivo methods for chronic pain based
on the fear-avoidance model with an emotion regulation
approach informed by procedures in Dialectical Behavior
Therapy (DBT).
- Validation (soothing emotions), dialectics (acceptance vs
change)
- Extensive (emotion regulation) skills training
- Exposure to feared movements and activities but also to
any other relevant target/stimulus
2019-02-25 8
Hybrid (10-15 sessions)
2019-02-25 9
Treatment stageI. Building a working relationship, soothing distress and developing relevant goals II. Developing skills to prepare for exposure and improve regulation of pain and emotion in everyday lifeIII. Exposure for emotions and movementsIV. Training context sensitivity; applying skills in tune with environmental demandsV. Maintaining and refining
iCBT (8 modules)
2019-02-25 10
Module, theme1: Introduction, pain education2: Coping with pain through graded exercise3: Coping with pain through behavioral strategies4: Coping with pain through cognitive strategies5: Mindfulness6: Stress and pain7: Sleep and pain8: Maintanance
Method
Randomized controlled trial
Chronic pain patients with co-occurring emotional problems
received either:
1. An individual treatment targeting processes that have
been shown to maintain emotional dysregulation
(Hybrid).
2. An active comparison condition receiving internet-
delivered pain management treatment based on CBT
principles (iCBT).
3. Outcome measured pre, mid, post treatment and 9
month follow up
The Ethics Review Board in Uppsala approved the study (2015/479), trial was preregistered at Clinicaltrails.gov (NCT02808286).
2019-02-25 12
2019-02-25 13
2019-02-25 14
2019-02-25 15
Sample characteristicsHybrid (n=58) iCBT (n=57)
Gender N (% women) 52 (89.7%) 44 (77.2%)
Age (mean (SD)) 45 (12) 44 (12)
Pain locations
▪ Back, neck and/or shoulders
▪ Legs and arms
▪ Other areas
58 (100%)
58 (100%)
16 (27.6%)
57 (100%)
57 (100%)
15 (26.3%)
Pain duration (median years (IQR)) 11 (11) 9 (12)
Education N (% university or above) 22 (37.9) 23 (40.4)
Occupational status (N (%))
▪ Working
▪ Unemployed
▪ Student
▪ Pensioner
▪ Other
33 (56.9%)
3 (5.2%)
3 (5.2%)
9 (15.5%)
10 (17.2%)
34 (59.6%)
4 (7%)
4 (7%)
6 (10.5%)
9 (15.8%)
Sick leave (N, % during last year)
▪ 0-14 days
▪ 15-180 days
▪ 181-365 days
25 (43.1%)
8 (13.8%)
25 (43.1%)
25 (43.9%)
11 (19.3%)
21 (36.8%)
Self reported diagnose
Diagnose (self-reported)▪ Fibromyalgia
▪ Chronic pain, not further specified
▪ Whiplash
▪ Other
20.7%58.6%10.3%10.3%
26.6%45.3%7.8%
20.4%
2019-02-25 17
2019-02-25 18
Hybrid (n=58) iCBT (n=57)
Psychiatric comorbidity (MINI-criteria)¹
▪ Not fulfilling disorder criteria
▪ Major depressive disorder
▪ Anxiety disorder
▪ Comorbid depressive and anxiety disorder
▪ Neuropsychiatric impairment ²
(n=52)
16 (30.8%)
24 (46%)
29 (55.8%)
17 (32.7%)
3 (5.8%)
(n=55)
23 (41.8%)
21 (38.2%)
24 (43.6%)
13 (23.6%)
1 (1.8%)
Screening measures (mean (SD))
▪ Function (ÖMPSQ) (0-40)
▪ HADS anxiety (0-21)
▪ HADS depression (0-21)
21 (7.5)
12.2 (4.0)
11.4 (3.8)
21.7 (7.3)
11.2 (4.1)
11.8 (4.3)
Questions
1. Is the hybrid treatment acceptable and well received by
patients?
2. Does a hybrid treatment lead to a decrease in comorbid
emotional symptoms, and an increase in functional ability?
3. Does a hybrid treatment lead to better treatment effect on the
above outcome variables compared to the active comparison
group?
4. Are therapeutic effects of the hybrid treatment mediated by
changes in emotion regulation?
5. Are therapeutic effects or the mediation of effects moderated by
patient characteristics (specifically: severity of emotional
problems)?
20
Hybrid iCBT
Satisfaction (0-10), median (IQR) 9 (2) 7 (5)***
Global improvement (0-10), mean (SD)
6.6 (2.1) 4.9 (2.4) **
Adverse events reported, n (%) 6 (13%) 11 (26.2%)
Acceptibility ratings
21
Patient self reported impression of global improvement
22
0 10 20 30 40 50 60 70 80
Drop-out before treatment start
< 25% completed
25-75% completed
>75 completed
% treatment completed
iCBT Hybrid
Results
Both groups improve:
Hybrid treatment within-group effect sizes ranging from d=0.35
(pain intensity) to d=1.01 (depressive symptoms) at post-treatment
and from d=0.40 (pain intensity) to d=1.17 (pain interference) at
follow-up.
iCBT within-group effect sizes ranging from d=0.31 (pain intensity)
to d=0.76 (depression) at post-treatment and d=0.60 (anxiety) to
d=0.73 (pain catastrophizing) at follow-up.
2019-02-25 23
Results: differences between conditions, FU
2019-02-25 24
0
10
20
30
40
50
60
70
80
Hybrid iCBT
% moderately to severlydepressed
% pre moderate to severe depressive symptoms
% FU moderate to severe depressive symptoms
2019-02-25 25
0
10
20
30
40
50
60
70
80
90
Hybrid iCBT
% likely anxiety disorder
% pre likely anxiety disorder % FU likely anxiety disorder
2019-02-25 26
0
5
10
15
20
25
30
35
40
45
Hybrid iCBT
% clinical level pain catastrophizing
% pre clinical level catastrophizing
% FU clinical level catastrophizing
2019-02-25 27
Preliminary results: emotion regulation mediated
differential improvement on depression
2019-02-25 28
Conclusions
• Acceptable and effective in incrementily changing interference,
depression and possibly catastrophizing
• Preliminary: emotional improvement mediated by change in
emotion regulation skills
• Preliminary: most benificial for patients with comorbid disorders
of clinical level
2019-02-25 29
Future
• Implementation
• What context?
• Improvements in the protocol?
• Possible in (possible) other formats, including otherprofessions?
• Training and competency.
• Future scientific work
• Further analyse and publish mediation and moderation
• Explore the role of context sensitivity
• Record linkage to further explore effects on medication use and work ability.
2019-02-25 30
Future work
0369
12151821242730333639424548515457606366697275
Hybrid iCBT
Medication use at 9 months FU
opioids psychofarmaca
2019-02-25 32
Opioids Psykotropic Op + Psyk
Madras hi/low 6,53 (CI 2.31-18.46)* 2,77 (CI 1,05-7,22)* 8,09 (CI 1.52-42.88)*
PCS hi/low 1,98 (CI 0.74-5.30) 3,00 (CI 1.16-7.80)* 2,15 (CI 0.50-9.24)
GAD hi/low 1,48 (CI 0.52-4.24) 2,57 (CI 0.95-6.94) 1,83 (CI 0.40-8.30)
LISAT hi/low 0,50 (CI 0.18-1.33) 0.74 (CI 0.30- 1.86) 0.59 (CI 0.13-2.61)
MPI-Interference hi/low 4,39 (CI 1.46-13.21)* 3,26 (CI 1.20-8.82)* 3,07 (CI 0.59-16.09)
Katja Boersma, ÖU, CHAMP
Steven Linton, ÖU, CHAMP
Ida Flink, ÖU, CHAMP
Martin Södermark, Liu, rehabcenter Lnkp
Sara Nygren, ÖU, CHAMP
Ester Klein Strandberg, ÖU, CHAMP
Maria Lind, rehabcenter USÖ
Marie Blom, rehabcenter Lnkp
Alan Fruzetti, University of Nevada
Mark Lumley, Wayne State University
Thomas Overmeer, Mälardalen Högskola
Monica Buhrman, Akademiska, Uppsala
Björn Gerdle, Linköping University